Research
Hormonal
Semaglutide is associated with cardiovascular risk reduction.
Practitioners can consider semaglutide as a potential option for reducing cardiovascular risk in adults.
StrongSupportsmedium confidence
Clinical trials have observed associations of semaglutide with cardiovascular risk reduction.
Why this rating
The claim is based on clinical trials, which are high-quality evidence.
Source
Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Receptor Agonist) Therapy
Leslie W. Nelson et al. · American Journal of Roentgenology · 2024
otherCited 26×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →